GYRE Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
32.9M
+13.2%
29.1M
+29.2%
22.5M
-39.5%
37.2M
+13.8%
32.7M
Cost of Revenue
1.9M
-11.9%
2.2M
+80.0%
1.2M
-29.6%
1.7M
+7.1%
1.6M
Gross Profit
31.0M
+15.2%
26.9M
+26.3%
21.3M
-39.9%
35.5M
+14.1%
31.1M
Operating Expenses
32.5M
-21.2%
41.3M
+34.6%
30.6M
-13.3%
35.3M
+19.5%
29.6M
R&D
8.5M
-55.5%
19.1M
+184.0%
6.7M
+39.9%
4.8M
-38.2%
7.8M
SG&A
23.9M
+10.8%
21.6M
+1.2%
21.4M
-30.0%
30.5M
+40.1%
21.8M
Operating Income
-1520000
+89.4%
-14363000
-53.5%
-9355000
-7895.8%
120.0K
-92.0%
1.5M
EBITDA
-1053000
+91.8%
-12880000
-48.3%
-8683000
-1165.4%
815.0K
-64.9%
2.3M
Net Income
-2478000
+82.6%
-14270000
-44.8%
-9858000
-621.7%
-1366000
-170.9%
1.9M
EPS (Basic)
$-0.04
+66.7%
$-0.12
-20.0%
$-0.10
-400.0%
$-0.02
-300.0%
$0.01
EPS (Diluted)
$-0.04
+66.7%
$-0.12
-20.0%
$-0.10
-900.0%
$-0.01
-200.0%
$0.01
Shares (Diluted)
106.3M
+5.6%
100.6M
+10.2%
91.3M
-22.3%
117.6M
+13.1%
104.0M
Gyre Therapeutics (GYRE) — Financials